Invention Grant
- Patent Title: Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery
-
Application No.: US16424351Application Date: 2019-05-28
-
Publication No.: US11090346B2Publication Date: 2021-08-17
- Inventor: Kenda Hansen , Kathleen Grave
- Applicant: InBold Inc.
- Applicant Address: US CA Santa Cruz
- Assignee: InBold Inc.
- Current Assignee: InBold Inc.
- Current Assignee Address: US CA Santa Cruz
- Agency: Morrison & Foerster LLP
- Main IPC: A61K36/185
- IPC: A61K36/185 ; A61K47/36 ; A61K31/714 ; A61K38/48 ; A61K47/46 ; A61K47/26 ; A61K47/12 ; A61K31/05 ; A61K9/00 ; A61K31/192 ; A61K31/352 ; A61K47/38

Abstract:
A formulation includes a cannabinoid extract that is pharmaceutically effective by systemic delivery via a recipient's oral mucosal lining. The method of delivery avoids the digestive tract processing and liver metabolizing of the active ingredients of the formulation, whereby lower doses cause a desired therapeutic effect or other intended effect. Variations of the formulation include a cannabinoid extract and one or more of pregelatinized tapioca starch polymethylsilsesquioxane, bromelain, volume Fenugreek gum, vitamin B12, luo han guo fruit extract, mannitol, microcrystalline cellulose, sodium alginate, gellan gum, menthol Natural peppermint flavor or oil, Grapefruit flavored powder or oil, magnesium stearate and/or citric acid. The cannabinoid extract may include Tetrahydrocannabinol, tetrahydrocannabinolic acid, Cannabidiol, Cannabidiol acid, and/or other cannabinoid sourced from a Cannabis sativa plant. The formulation includes at least one cannabinoid in a volume and measure that is pharmaceutically effective and/or effectual in achieving an intended systemic state or response of the recipient.
Public/Granted literature
- US20200376057A1 Cannabinoid Composition and Method of Sublingual, Buccal and Oral Mucosa Delivery Public/Granted day:2020-12-03
Information query